Design Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Unaudited interim results. Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC molecules; it had no approved products and generated no product revenue.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $14.3 million | $8.5 million | $34.4 million | $17.4 million |
| General and administrative expense | $4.9 million | $2.8 million | $13.8 million | $7.3 million |
| Total operating expenses | $19.2 million | $11.3 million | $48.2 million | $24.7 million |
| Net loss | $17.7 million | $11.3 million | $46.0 million | $24.5 million |
| Net loss per share | $0.32 | $0.21 | $0.83 | $0.57 |
For the nine months, operating cash use was $36.2 million, versus $20.2 million in 2021. Investing cash use was $219.9 million, largely reflecting purchases of investment securities; financing provided $0.1 million, compared with $379.0 million in the prior-year period, when the IPO and preferred-stock financing occurred. Cash and cash equivalents were $42.5 million at September 30, 2022, and investment securities were $301.7 million. Together, cash, cash equivalents and investments totaled $344.2 million, down from $384.1 million at December 31, 2021.
Total assets were $354.6 million and stockholders’ equity was $340.9 million. Total liabilities were $13.6 million, including a $3.8 million operating lease liability; the filing reports no debt balance. Current assets were $348.5 million and current liabilities $10.4 million. No operating margin is meaningful because the company had no product revenue and recorded operating expenses. Accumulated deficit was $93.4 million.
Material changes versus prior comparable periods
- Q3 operating expenses rose $7.9 million year over year; nine-month expenses rose $23.5 million. Management cited DT-216 clinical advancement, support for early-stage programs, increased personnel and public-company costs.
- Nine-month R&D expense included $12.3 million attributed to FA candidate DT-216, versus none in the prior-year period. General and administrative costs also increased, including stock-based compensation, insurance and professional fees.
- Nine-month net loss increased by $21.5 million year over year. Other income was $2.2 million for the nine months, compared with $0.2 million in 2021.
- Available-for-sale securities had $3.9 million of unrealized losses at September 30, 2022, recorded in accumulated other comprehensive loss. The company attributed the declines primarily to interest-rate changes and reported no material credit deterioration.
Outlook, programs and risks
- Management said existing cash, cash equivalents and investments were expected to fund planned operating expenses and capital requirements for more than 12 months following the filing. The company also stated that it would need substantial additional funding to take candidates through regulatory approval; estimates depend on assumptions and actual cash use could be faster.
- DT-216, the lead Friedreich ataxia (FA) candidate, had FDA IND clearance and Fast Track designation. The first cohort of its Phase 1 single-ascending-dose trial had completed dosing; initial data were expected in December 2022. Patient dosing had recently begun in the multiple-ascending-dose trial.
- For the myotonic dystrophy type-1 (DM1) program, the company expected to complete IND-enabling studies and seek regulatory clearance for a first-in-human trial in 2023. Its Fuchs endothelial corneal dystrophy program remained in preclinical research.
- Management expected operating expenses and losses to rise as clinical, preclinical, manufacturing and organizational activities expand. Development timelines, costs and outcomes remain uncertain; the company has only one candidate in clinical development and has never generated product-sales revenue.
- Key risks include clinical safety or efficacy setbacks, regulatory and enrollment delays, reliance on third-party manufacturers and research providers, competition, intellectual-property protection, and potential financing needs and dilution. The filing also cites inflation, supply-chain and labor constraints, COVID-19 and geopolitical uncertainty.
- The company had an effective shelf registration statement authorizing up to $300 million of securities, including a $100 million ATM program; no ATM shares had been sold as of September 30, 2022.
- Related-party arrangements include laboratory and office leases with an entity managed by the executive chairperson. A separate consulting agreement with a related party carries a potential $240,000 termination fee if terminated unilaterally by the company other than for cause; no liability was recorded because timing was undetermined. No material litigation or contingent liabilities were reported.
Important facts for investors to verify
- Whether DT-216 Phase 1 data and subsequent trial progress met the disclosed expectations, including the status and timing of the multiple-ascending-dose study.
- Current cash, cash equivalents and investment balances, operating cash burn, and the assumptions behind management’s stated runway and future financing needs.
- Progress toward the DM1 IND-enabling and first-in-human milestones, and developments in the preclinical portfolio.
- Changes in R&D spending, related-party expenses and lease commitments, securities valuation losses, and any use of the shelf or ATM program.